AustraliaHealth

Cambium Bio (ASX:CMB) announced that the US Food and Drug Administration confirmed a streamlined approval pathway for its flagship candidate, Elate Ocular.

Nyrada (ASX:NYR) announced the activation of its first clinical trial site for the PROTECT-MI Phase 2a study.

Australian Health Minister Mark Butler is set to announce the removal of out-of-pocket costs for essential aged-care services.

Invion (ASX:IVX) announced the expansion of its clinical trial for INV043, moving into the final stage of its current non-melanoma skin cancer study.

Recce Pharmaceuticals (ASX:RCE) achieves a regulatory milestone as Indonesia's BPOM clears its Phase 3 clinical trial site for diabetic foot infection treatment.

Nexalis Therapeutics (ASX:NX1) announced a clinical breakthrough with the screening of the first patient in its Phase 2 clinical trial for IRX-211.

Radiopharm Theranostics (ASX:RAD) unveiled initial data from its Phase 1 "HEAT" first-in-human clinical trial.

4DMedical (ASX:4DX) announced a new strategic contract with pharmaceutical giant GlaxoSmithKline.

Monash IVF Group (ASX:MVF) has rejected a revised, unsolicited takeover bid from a consortium led by Genesis Capital and Washington H. Soul Pattinson (ASX:SOL).

Orthocell (ASX:OCC) completed its first Remplir surgical case in the US DoD/VA network.

Immuron (ASX:IMC) recorded a double-digit increase in global sales for the third quarter of fiscal year 2026.

Radiopharm Theranostics (ASX:RAD) announced the completion of enrolment for its US Phase 2b imaging trial of RAD 101.